Airna estimates approximately 100,000 people in the U.S. have AATD, and the company is preparing to launch a Phase 1/2 trial for its lead program.
Founders
Thorsten Stafforst, Jin Billy Li
Company Description
Airna is a biotechnology startup developing RNA editing treatments, specifically targeting alpha-1 antitrypsin deficiency (AATD) by repairing faulty RNA to produce functional AAT protein, thereby reducing the risk of associated lung and liver diseases.
Market
RNA editing treatments for alpha-1 antitrypsin deficiency